Matches in SemOpenAlex for { <https://semopenalex.org/work/W4248862816> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- W4248862816 endingPage "4662" @default.
- W4248862816 startingPage "4662" @default.
- W4248862816 abstract "4662 Background: Pulmonary metastases of renal cell carcinoma (RCC) are associated with poor prognosis especially when the disease is rapidly progressing. The lung is a common site for metastases and respiratory failure is a common cause of death in patients with RCC. Inhalation therapy with IL-2 is thus an appealing method for palliation. This multi-center study summarizes the national experience with IL-2 inhalation in patients with lung metastases of RCC. Methods: All the patients had to have radiologically documented lung metastases, had to be able to comply with inhalation technique, and were not candidates for other treatment options. Treatment included 3 daily inhalations of 18 MU IL-2 by using a Salvia Lifetec Jetair inhalator. Treatment had to be continued until progression or complete response or life threatening toxicity or patient's refusal. Response was evaluated according to RECIST. Results: Forty patients (median 66.5 years), with histological or cytological diagnosis of RCC were enrolled. Nephrectomy was performed in a total of 32 patients. Previous treatments for metastatic disease included various combinations of systemic chemo-immunotherapy in 12 patients. Twenty-eight patients were systemic-treatment-naïve.The observed true response rate was 2.5% and disease stabilization rate was 55%. The disease-control rate (partial response plus disease stabilization rate) reached 57.5%. Time to progression ranged from 0.3 (in case of rapidly progressing disease) to more than 43 months, with a median of 8.7 months. The side effects included cough in 8 patients, weakness in 9, dyspnea in 3, fever in 2, sleepiness in 1, asthenia in 1, decreased appetite in 1, and abdominal pain in 1. Conclusions: Inhalation of IL-2 for treating pulmonary metastases of RCC is feasible, tolerable, and efficacious in controlling a progressive disease for considerable periods of time. Definition of response of biological therapy by RECIST system should be re-assessed and modified: stable disease should be regarded as a favorable and an important response. No significant financial relationships to disclose." @default.
- W4248862816 created "2022-05-12" @default.
- W4248862816 creator A5003267211 @default.
- W4248862816 creator A5037950672 @default.
- W4248862816 creator A5039823022 @default.
- W4248862816 creator A5047927992 @default.
- W4248862816 creator A5052653659 @default.
- W4248862816 creator A5073983162 @default.
- W4248862816 creator A5085467533 @default.
- W4248862816 creator A5088284780 @default.
- W4248862816 creator A5088859638 @default.
- W4248862816 creator A5089230523 @default.
- W4248862816 date "2004-07-15" @default.
- W4248862816 modified "2023-10-16" @default.
- W4248862816 title "Targeting pulmonary metastases of renal cell carcinoma by inhalation of Interleukin-2 (IL-2)" @default.
- W4248862816 doi "https://doi.org/10.1200/jco.2004.22.14_suppl.4662" @default.
- W4248862816 hasPublicationYear "2004" @default.
- W4248862816 type Work @default.
- W4248862816 citedByCount "0" @default.
- W4248862816 crossrefType "journal-article" @default.
- W4248862816 hasAuthorship W4248862816A5003267211 @default.
- W4248862816 hasAuthorship W4248862816A5037950672 @default.
- W4248862816 hasAuthorship W4248862816A5039823022 @default.
- W4248862816 hasAuthorship W4248862816A5047927992 @default.
- W4248862816 hasAuthorship W4248862816A5052653659 @default.
- W4248862816 hasAuthorship W4248862816A5073983162 @default.
- W4248862816 hasAuthorship W4248862816A5085467533 @default.
- W4248862816 hasAuthorship W4248862816A5088284780 @default.
- W4248862816 hasAuthorship W4248862816A5088859638 @default.
- W4248862816 hasAuthorship W4248862816A5089230523 @default.
- W4248862816 hasConcept C126322002 @default.
- W4248862816 hasConcept C141071460 @default.
- W4248862816 hasConcept C2776256026 @default.
- W4248862816 hasConcept C2776888751 @default.
- W4248862816 hasConcept C2776954882 @default.
- W4248862816 hasConcept C2777472916 @default.
- W4248862816 hasConcept C2777714996 @default.
- W4248862816 hasConcept C2778822529 @default.
- W4248862816 hasConcept C2779134260 @default.
- W4248862816 hasConcept C2780091579 @default.
- W4248862816 hasConcept C2780227381 @default.
- W4248862816 hasConcept C42219234 @default.
- W4248862816 hasConcept C71924100 @default.
- W4248862816 hasConcept C90924648 @default.
- W4248862816 hasConceptScore W4248862816C126322002 @default.
- W4248862816 hasConceptScore W4248862816C141071460 @default.
- W4248862816 hasConceptScore W4248862816C2776256026 @default.
- W4248862816 hasConceptScore W4248862816C2776888751 @default.
- W4248862816 hasConceptScore W4248862816C2776954882 @default.
- W4248862816 hasConceptScore W4248862816C2777472916 @default.
- W4248862816 hasConceptScore W4248862816C2777714996 @default.
- W4248862816 hasConceptScore W4248862816C2778822529 @default.
- W4248862816 hasConceptScore W4248862816C2779134260 @default.
- W4248862816 hasConceptScore W4248862816C2780091579 @default.
- W4248862816 hasConceptScore W4248862816C2780227381 @default.
- W4248862816 hasConceptScore W4248862816C42219234 @default.
- W4248862816 hasConceptScore W4248862816C71924100 @default.
- W4248862816 hasConceptScore W4248862816C90924648 @default.
- W4248862816 hasIssue "14_suppl" @default.
- W4248862816 hasLocation W42488628161 @default.
- W4248862816 hasOpenAccess W4248862816 @default.
- W4248862816 hasPrimaryLocation W42488628161 @default.
- W4248862816 hasRelatedWork W14962949 @default.
- W4248862816 hasRelatedWork W1695334674 @default.
- W4248862816 hasRelatedWork W1976968719 @default.
- W4248862816 hasRelatedWork W2033892848 @default.
- W4248862816 hasRelatedWork W2045737731 @default.
- W4248862816 hasRelatedWork W2348809255 @default.
- W4248862816 hasRelatedWork W2414205618 @default.
- W4248862816 hasRelatedWork W2418997211 @default.
- W4248862816 hasRelatedWork W4211029083 @default.
- W4248862816 hasRelatedWork W4311332201 @default.
- W4248862816 hasVolume "22" @default.
- W4248862816 isParatext "false" @default.
- W4248862816 isRetracted "false" @default.
- W4248862816 workType "article" @default.